Tracking the FATE option chain helps you see every strike and expiry on Fate Therapeutics Inc in one view, so you can quickly identify the contracts that fit your thesis and your risk. Fate Therapeutics Inc's option chain lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of FATE options activity at a glance. Use our scanner to monitor the FATE option chain in real time and filter for the FATE options trades that actually meet your criteria.
An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For FATE stock options, the chain shows side-by-side call and put data, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading the FATE option chain effectively means looking beyond the last price — implied volatility by strike, volume-to-open-interest ratios, and bid-ask spreads all tell you where FATE stock options are being actively traded and where they are not.
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors.
The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Credit spreads, long calls, iron condors, calendar trades — every strategy starts with the same raw material: a clean, complete option chain. Our scanner pulls Fate Therapeutics Inc's full chain across every expiry, highlights the most liquid strikes, and lets you screen FATE options by the metrics that matter, from IV skew to volume surges. Stop scrolling through endless rows of FATE stock options — let the full option chain come to you, pre-filtered and ready to trade.
